Abstract: Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis.
Type:
Grant
Filed:
April 8, 2010
Date of Patent:
April 8, 2014
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Joachim Struck, Wolfgang Weglöhner
Abstract: Subject of the present invention is a method of assessing the susceptibility of a subject to acquire cancer and/or assessing the risk of cancer mortality for a subject, who has not had clinically manifest cancer and/or does not have clinically manifest cancer at the time when applying this method.
Type:
Application
Filed:
June 17, 2011
Publication date:
February 20, 2014
Applicant:
B.R.A.H.M.S GMBH
Inventors:
Andreas Bergmann, Joachim Struck, Olle Melander
Abstract: The present invention relates to an in vitro method for medical diagnosis, prognosis and therapy follow-up for patients having a cardiac disease or being suspected of developing or having a cardiac disease comprising the steps of: providing a sample of a patient having a cardiac disease or being suspected of developing or having a cardiac disease, determining amino-terminal proANp or partial peptides thereof having from 12 to 98 amino acids in said sample using at least one antibody that binds specifically to a partial sequence of amino-terminal proANP, attributing the determined amino-terminal proANP level or the level of partial peptides thereof to a clinical picture wherein the attribution is carried out independent of the BMI of the patient. The present invention further concerns a rapid test assay and a kit for conducting the method of the present invention and the use of antibodies suitable for the method and assays according to the present invention.
Type:
Grant
Filed:
May 6, 2008
Date of Patent:
February 11, 2014
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Jana Papassotiriou, Joachim Struck, Nils Morgenthaler, Stefan Anker
Abstract: The present invention relates to the determination of the level of marker peptides in a sample derived from a bodily fluid of a subject presenting to the emergency department with non-specific complaints.
Type:
Application
Filed:
October 31, 2011
Publication date:
November 14, 2013
Applicant:
B.R.A.H.M.S GMBH
Inventors:
Joachim Struck, Sven Giersdorf, Oliver Hartmann, Roland Bingisser, Christian Nickel
Abstract: The invention relates to a method for diagnosis and/or risk classification for acute coronary syndrome (ACS), in particular for acute myocardial infarct (AMI) and angina pectoris (AP) and/or a post-myocardial infarct, wherein a determination of the C-terminal pro-endothelin (CT-proET-1) or fragments and partial peptides therefrom, is carried out in combination with NT-proBNP.
Type:
Grant
Filed:
December 22, 2007
Date of Patent:
September 3, 2013
Assignee:
B.R.A.H.M.S GmbH
Inventors:
Andreas Bergmann, Nils Morgenthaler, Jana Papassotiriou, Joachim Struck, Leong L. Ng
Abstract: The field of the present invention is the diagnosis and/or prediction and/or therapy follow-up of bacterial infections in subjects suffering from dyspnea. It is a subject of the present invention to provide a method for the diagnosis and/or prediction and/or therapy follow-up of bacterial infections in subjects suffering from dyspnea.
Abstract: The present invention relates to the use of affinity-purified polyclonal human autoantibodies against the TSH receptor (TSHR-Auto-Ab), obtained from the serum of Graves' disease patients and which have been purified to obtain biochemical homogeneity and comprise a specific activity of at least 1 IU/mg protein (human immunoglobulin). Also disclosed is the use of animal antibodies, which compete with the former for the binding sites of a functional human TSH receptor, as a specific binding reagent in an immunological determination method for the clinical identification of autoantibodies against the TSH receptor (TSHR-Auto-Ab) in a sample of a biological fluid of a patient to be examined for Graves' disease.
Type:
Grant
Filed:
October 31, 2003
Date of Patent:
August 6, 2013
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Sabine Costagliola, Gilbert Vassart
Abstract: The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis.
Type:
Grant
Filed:
October 26, 2007
Date of Patent:
August 6, 2013
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Nils Morgenthaler, Jana Papassotiriou, Joachim Struck, Leong L. Ng
Abstract: The invention relates to a method for diagnosis of infections or inflammatory diseases of the airways and lungs with associated heart failure, wherein the marker procalcitonin or a partial sequence thereof is determined in a patient to be examined, in particular for classifying patients according to risk. The invention further relates to a diagnostic device and kit for carrying out the method.
Type:
Grant
Filed:
October 1, 2007
Date of Patent:
June 18, 2013
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Nils Morgenthaler, Jana Papassotiriou, Joachim Struck
Abstract: Described herein is an in vitro method for the determination of the formation of endothelins in serious diseases, in particular cardiovascular diseases, inflammations, sepsis and cancer, in whole blood, plasma or serum of a human patient, in which relatively long-lived peptide fragments of the processed primary prepro- or proendothelins are determined which contain neither the actual biologically active endothelin nor its direct precursor big endothelin. In particular, disclosed are antibodies and kits for selectively detecting these fragments.
Abstract: The present invention provides an immunodiagnostic method for determining procalcitonin and procalcitonin derivatives in a biological sample of a patient, in particular in the monitoring and control of treatment and the monitoring of the progression of a local or systemic bacterial infection, inflammation, sepsis or neurodegenerative disease. In particular, the method detects molecular forms of intact procalcitonin 1-116, or procalcitonin partial peptides derived therefrom that retain amino acids alanine and proline (Ala-Pro, AP) in positions 1 and 2 of the amino terminus of the complete procalcitonin 1-116. The method uses antibodies that selectively bind an epitope comprising amino acids 1 and 2 of procalcitonin 1-116 (SEQ ID NO: 1) and can distinguish between intact procalcitonin 1-116 and for example, procalcitonin 3-116.
Abstract: The invention relates to the use of carbamoyl synthetase 1 (CPS 1) as a humoral biomarker in in vitro methods for early diagnosis and detection, progress prognosis, the evaluation of the severity, and the progress evaluation of tumor diseases and chronic inflammatory intestinal diseases.
Abstract: The present invention relates to the determination of the level of marker peptides in a sample derived from a bodily fluid of a subject presenting with non-specific complaints.
Type:
Application
Filed:
March 8, 2011
Publication date:
April 18, 2013
Applicant:
B.R.A.H.M.S GMBH
Inventors:
Joachim Struck, Christian Nickel, Roland Bingisser, Sven Giersdorf, Oliver Hartmann
Abstract: The invention relates to an in vitro method for determining procalcitonin levels in plasma and urine as a diagnostic marker to identify patients with urinary tract infections, in vitro methods to perform said determination, a kit for the diagnosis of patients with urinary tract infections, and the usefulness of procalcitonin in the diagnosis urinary tract infections.
Type:
Application
Filed:
March 15, 2011
Publication date:
April 4, 2013
Applicant:
B.R.A.H.M.S GMBH
Inventors:
Francesco Giunta, Francesco Forfori, Giada Seri
Abstract: The present invention relates to an in vitro method for the diagnosis and treatment guidance of a bacterial infection in patients suffering from an acute ischemic or hemorrhagic stroke, comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said patient and the correlation of the determined level to the diagnosis of a bacterial infection in said patient.
Type:
Grant
Filed:
October 12, 2010
Date of Patent:
February 26, 2013
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Oliver Hartmann, Frauke Hein, Beat Müller
Abstract: The present invention provides an immunodiagnostic method for determining procalcitonin and procalcitonin derivatives in a biological sample of a patient for diagnostic purposes, in particular in the monitoring and control of treatment and the monitoring of the progression of a local or systemic bacterial infection, inflammation, sepsis or neurodegenerative disease. In particular, the method detects molecular forms of procalcitonin, or procalcitonin partial peptides derived therefrom, having the amino acids alanine and proline (Ala-Pro, AP) in positions 1 and 2 of the amino terminus of the complete procalcitonin 1-116 (SEQ ID NO: 1.) Also disclosed are antibodies and kits for carrying out such a method.
Abstract: The invention refers to a method for determining a marker in a small volume of a sample of a bodily fluid, the method comprising the steps of: providing a flow test element having a plurality of functional zones (3, 4, 5, 6, 7), the plurality of functional zones (3, 4, 5, 6, 7) being at least partially fluidly connected and comprising an application zone (3) and a testing zone (5) fluidly connected to the application zone (3) and configured for determination of a marker in a bodily fluid and/or a constituent of the bodily fluid, applying a small volume of a liquid sample to the sample application zone (3) of the flow test element, determining a correct test performance, wherein the step of determining correct test performance comprises the steps of measuring at least one optical parameter for one or more functional zones (3; 4; 5; 6; 7), comparing the at least one optical parameter measured to at least one predefined optical parameter assigned to the one or more functional zones (3; 4; 5; 6; 7), and, if the c
Abstract: An in vitro process for the detection and early detection of neurodegenerative diseases, for determination of the severity, and to evaluate the progression of and render a prognoses of neurogenerative diseases, in a patient suffering from a subjectively or objectively detectable cognitive impairment, by determining the concentration of an analyte selected from natriuretic peptides, in particular ANP, and, if necessary, BNP and/or CNP in a biological fluid of the patient, whereby the determination of the analyte is performed directly and/or indirectly as the determination of a relevant co-peptide generated from a mutual propeptide, and is based upon the measured concentration of the determined analyte thus making it possible to form conclusions about a neurodegenerative disease or an early form typical of such a disease or the course of the disease and/or the success of the efforts to relieve or prevent the disease.
Type:
Grant
Filed:
May 15, 2007
Date of Patent:
October 30, 2012
Assignee:
B.R.A.H.M.S GmbH
Inventors:
Andreas Bergmann, Andrea Ernst, Harald Hampel